Journal of Clinical and Translational Hepatology

Journal of Clinical and Translational Hepatology

Friday, 12 / 04 / 2020

Articles

FibroScan Detection of Fatty Liver/Liver Fibrosis in 2266 Cases of Chronic Hepatitis B

ORIGINAL ARTICLE

FibroScan Detection of Fatty Liver/Liver Fibrosis in 2266 Cases of Chronic Hepatitis B

Tingshan He, Jing Li, Yanling Ouyang, Guotao Lv, Xiaofeng Ceng, Zhiqiao Zhang and Jianqiang Ding

Department of Infectious Diseases, Shunde Hospital, Southern Medical University, Shunde, Guangdong, China
Department of Pathology, Shunde Hospital, Southern Medical University, Shunde, Guangdong, China

*Correspondence to:Jianqiang Ding, Department of Infectious Diseases, Shunde Hospital, Southern Medical University, 1#Jiazi Road, Shunde, Guangdong 528308, China. Tel: +86-15218853076, E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. ; Zhiqiao Zhang, Department of Infectious Diseases, Shunde Hospital, Southern Medical University, 1#Jiazi Rd, Shunde, Guangdong 528308, China. Tel: +86-15876129625E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Journal of Clinical and Translational Hepatology 2020;8(2):113-119 DOI: 10.14218/JCTH.2019.00053
Received: October 14, 2019 Accepted: March 18, 2020 Published online: April 28, 2020

Abstract

Background and Aims: FibroScan is used to determine liver stiffness and controlled attenuation parameter (referred to as CAP) scores in patients, including those with chronic hepatitis B (CHB). We used FibroScan to detect the incidence of fatty liver and fibrosis in CHB patients, and to assess the correlation of FibroScan measurements with blood chemistry tests.

Methods: CHB patients enrolled in this study were divided independently for three separate analyses (of fibrosis, cirrhosis, and fatty liver) based on FibroScan results. Basic information, blood chemistry test results, liver fibrosis parameters, and FibroScan results were collected. T-tests and Pearson’s analyses were used to analyze the correlations between FibroScan liver stiffness measurement/CAP values and liver function, blood fat, uric acid metabolite, fibrosis, and hepatitis B virus load.

Results: A total of 2266 CHB patients were enrolled in the study and divided into three groups: non-significant and significant fibrosis; non-cirrhosis and early cirrhosis; and non-fatty and fatty liver. Spearman’s statistical analyses showed that liver stiffness measurement or CAP values correlated with sex (r=0.137), age (r=0.119),glutamic-pyruvic transaminase (r=0.082), glutamic-oxaloacetic transaminase (r=–0.172), gamma-glutamyltransferase (r=0.225), albumin (r=0.150), globulin (r=–0.107), total bilirubin (r=–0.132), direct bilirubin (r=–0.145), white blood cell count (r=0.254), hemoglobin (r=0.205), platelets (r=0.206), total cholesterol (r=0.214), high density lipoprotein (r=–0.243), low density lipoprotein (r=0.255), apolipoprotein B (r=0.217), hyaluronic acid (r=–0.069), laminin (r=–0.188), procollagen type IV (r=–0.067)and hepatitis B viral DNA load (r=–0.216).

Conclusions: FibroScan is a non-invasive device that can detect the occurrence of fatty liver or liver fibrosis in CHB patients.

Keywords

FibroScan, Chronic hepatitis B, Fatty liver, Liver fibrosis, Cirrhosis

Journal of Clinical and Translational Hepatology 2020 vol. 8, 113-119  [ Html ] [ PDF Full-text ]

© The Authors 2020. This article is published under the terms of the Creative Commons Attribution-Noncommercial License (CC BY-NC 4.0), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non-commercial and is otherwise in compliance with the license.

 logo

You are here: Home